Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Sponsor
Sun Yat-sen University
Study ID
NCT07192185
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • FOLFOX — DRUG
    oxaliplatin 85mg/m2 + leucovorin 400mg/m2 + 5-fu 400mg/m2 + 5-fu 2400mg/m2 46h iv.drip Q3W
  • Atezolizumab & Bevacizumab — DRUG
    Atezolizumab 1200mg iv.drip + Bevacizumab 15mg/kg iv.drip Q3w

Study Details

Atezolizumab plus bevacizumab is the first-line treatment for advanced hepatocellular carcinoma (HCC). However, the effect of the second-line treatment after the progress of Atezolizumab plus bevacizumab therapy remains unsatisfactory. This is a prospective trial to investigate the efficacy and safety of systemic chemotherapy with FOLFOX plus Atezolizumab \& bevacizumab as second-line treatment for patients with advanced HCC who previously received atezolizumab plus bevacizumab

Key Dates

Start date
Sep 17, 2025
Status verified
Sep 2025
Primary completion
Dec 1, 2026
Completion
Mar 1, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: FOLFOX+TA
    Systemic chemotherapy with FOLFOX plus Atezolizumab \& bevacizumab

Primary Outcome Measure

ORR via mRECIST [ Time Frame: 12 months ]

Central Contacts

Related Studies